1,546 results on '"Halfvarson, Jonas"'
Search Results
202. Restorative Surgery Is More Common in Ulcerative Colitis Patients With a High Income: A Population-Based Study
- Author
-
Nordenvall, Caroline, Westberg, Karin, Soderling, Jonas, Everhov, Asa H., Halfvarson, Jonas, Ludvigsson, Jonas F., Myrelid, Pär, Olen, Ola, Nordenvall, Caroline, Westberg, Karin, Soderling, Jonas, Everhov, Asa H., Halfvarson, Jonas, Ludvigsson, Jonas F., Myrelid, Pär, and Olen, Ola
- Abstract
BACKGROUND: To avoid a permanent stoma, restorative surgery is performed after the colectomy. Previous studies have shown that less than half of patients with ulcerative colitis undergo restorative surgery. OBJECTIVE: The primary aim was to explore the association between socioeconomic status and restorative surgery after colectomy. DESIGN: This was a nationwide register-based cohort study. SETTINGS: The study was conducted in Sweden. PATIENTS: All Swedish patients with ulcerative colitis who underwent colectomy between 1990 and 2017 at the age of 15 to 69 years were included. MAIN OUTCOME MEASURES: The main outcome was restorative surgery, and the secondary outcome was failure of the reconstruction (defined as the need for a new ileostomy after the reconstruction or nonreversal of a defunctioning stoma within 2 years of the reconstruction). To calculate HRs for restorative surgery after colectomy, as well as failure after restorative surgery, multivariable Cox regression models were performed (adjusted for sex, year of colectomy, colorectal cancer diagnosis, education, civil status, country of birth, income (quartiles 1 to 4, where Q4 represents highest income), hospital volume, and stratified by age). RESULTS: In all, 5969 patients with ulcerative colitis underwent colectomy, and of those, 2794 (46.8%) underwent restorative surgery. Restorative surgery was more common in patients with a high income at the time of colectomy (quartile 1, reference; quartile 2, 1.09 (0.98-1.21); quartile 3, 1.20 (1.07-1.34); quartile 4, 1.27 (1.13-1.43)) and less common in those born in a Nordic country than in immigrants born in a non-Nordic country (0.86 (0.74-0.99)), whereas no association was seen with educational level and civil status. There was no association between socioeconomic status and the risk of failure after restorative surgery. LIMITATIONS: The study was restricted to register data. CONCLUSIONS: Restorative surgery in ulcerative colitis appears to be more common in p, Funding Agencies|Region Stockholm; Bengt Ihre research fellowship; Karolinska Institutet foundationKarolinska Institutet; Karolinska Institutets Young Scholar Award from the Strategic Research Area Epidemiology Program; Swedish Medical Society; Bengt Ihre foundation
- Published
- 2021
- Full Text
- View/download PDF
203. Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue
- Author
-
Fart, Frida, Salihovic, Samira, McGlinchey, Aidan J, Gareau, Melanie G., Oresic, Matej, Halfvarson, Jonas, Hyötyläinen, Tuulia, Schoultz, Ida, Fart, Frida, Salihovic, Samira, McGlinchey, Aidan J, Gareau, Melanie G., Oresic, Matej, Halfvarson, Jonas, Hyötyläinen, Tuulia, and Schoultz, Ida
- Abstract
BACKGROUND: Environmental factors are strongly implicated in late-onset of inflammatory bowel disease. Here, we investigate whether high levels of perfluoroalkyl substances are associated with (1) late-onset inflammatory bowel disease, and (2) disturbances of the bile acid pool. We further explore the effect of the specific perfluoroalkyl substance perfluorooctanoic acid on intestinal barrier function in murine tissue. METHODS: Serum levels of perfluoroalkyl substances and bile acids were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole mass spectrometer in matched samples from patients with ulcerative colitis (n = 20) and Crohn's disease (n = 20) diagnosed at the age of ≥55 years. Age and sex-matched blood donors (n = 20), were used as healthy controls. Ex vivo Ussing chamber experiments were performed to assess the effect of perfluorooctanoic acid on ileal and colonic murine tissue (n = 9). RESULTS: The total amount of perfluoroalkyl substances was significantly increased in patients with ulcerative colitis compared to healthy controls and patients with Crohn's disease (p < .05). Ex vivo exposure to perfluorooctanoic acid induced a significantly altered ileal and colonic barrier function. The distribution of bile acids, as well as the correlation pattern between (1) perfluoroalkyl substances and (2) bile acids, differed between patient and control groups. DISCUSSION: Our results demonstrate that perfluoroalkyl substances levels are increased in patients with late-onset ulcerative colitis and may contribute to the disease by inducing a dysfunctional intestinal barrier., Funding Agencies:Faculty of Medicine and Health, Örebro University ORU2018/04457Bo Rydin foundation F0514Örebro Hospital Research Foundation OLL-790011
- Published
- 2021
- Full Text
- View/download PDF
204. Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease : A Scandinavian Population-Based Cohort Study
- Author
-
Erichsen, Rune, Olén, Ola, Sachs, Michael C., Pedersen, Lars, Halfvarson, Jonas, Askling, Johan, Ekbom, Anders, Ludvigsson, Jonas F., Sørensen, Henrik Toft, Erichsen, Rune, Olén, Ola, Sachs, Michael C., Pedersen, Lars, Halfvarson, Jonas, Askling, Johan, Ekbom, Anders, Ludvigsson, Jonas F., and Sørensen, Henrik Toft
- Abstract
Background: Inflammatory bowel disease (IBD) has been associated with hepatobiliary cancer, but existing evidence is poor. We evaluated risk of death from hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC) among patients with IBD. Methods: This Swedish/Danish population-based cohort study (1969-2017) followed patients with IBD and 1:10 matched population comparators from their diagnosis/match date until death, emigration, or end of follow-up. Results: Among the 97,496 patients with ulcerative colitis/963,026 comparators, we found 66/390 HCC-deaths, 120/173 ICC-deaths, and 91/220 ECC-deaths (median follow-up 10 years); the 10-year-mortality was 0.5% (per mille) for HCC, 0.6% for ICC, and 0.4% for ECC, which decreased to 0.3%, 0.4%, and 0.2%, respectively, in 2003-2017. Overall hazard ratios (HR) were 1.83 [95% confidence interval (CI), 1.41-2.38] for HCC-, 7.33 (95% CI, 5.81-9.25) for ICC-, and 4.46 (95% CI, 3.49-5.70) for ECC-deaths. A total of 22/66 HCC-deaths, 87/120 ICC-deaths, and 55/91 ECC-deaths occurred among patients with ulcerative colitis with primary sclerosing cholangitis (PSC), corresponding to 10-year-mortality of 6.7%, 26.2%, and 17.2%, respectively. Among 47,399 patients with Crohn's disease (median follow-up 11 years), 10-year-mortality from HCC (n = 28), ICC (n = 28), and ECC (n = 24) were 0.3%, 0.1%, and 0.3%, respectively, and corresponding HRs were 1.96 (95% CI, 1.31-2.93), 3.33 (95% CI, 2.19-5.09), and 3.10 (95% CI, 1.97-4.87). One of 28 HCC-deaths, 14/28 ICC-deaths (10-year-mortality 19%), and 12/24 ECC-deaths (10-year-mortality 14%) occurred after PSC. Conclusions: Risk of HCC-, ICC-, and ECC-deaths was low in patients with IBD and decreased over time. However, a large proportion of deaths occurred after PSC. Impact: Guidelines on specific surveillance strategies for patients with IBD with PSC, but not those without PSC, are needed., Funding agencies:Independent Research Fund Denmark 8020-00153B Young Scholar Award from the Strategic Research Area Epidemiology Program at Karolinska Institutet
- Published
- 2021
- Full Text
- View/download PDF
205. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease
- Author
-
Kalla, R., Adams, A. T., Bergemalm, Daniel, Vatn, S., Kennedy, N. A., Ricanek, P., Lindstrom, J., Ocklind, A., Hjelm, F., Ventham, N. T., Ho, G. T., Petren, C., Repsilber, Dirk, Söderholm, J., Pierik, M., D'Amato, M., Gomollón, F., Olbjorn, C., Jahnsen, J., Vatn, M. H., Halfvarson, Jonas, Satsangi, J., Kalla, R., Adams, A. T., Bergemalm, Daniel, Vatn, S., Kennedy, N. A., Ricanek, P., Lindstrom, J., Ocklind, A., Hjelm, F., Ventham, N. T., Ho, G. T., Petren, C., Repsilber, Dirk, Söderholm, J., Pierik, M., D'Amato, M., Gomollón, F., Olbjorn, C., Jahnsen, J., Vatn, M. H., Halfvarson, Jonas, and Satsangi, J.
- Abstract
BACKGROUND: Success in personalised medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay (PEA) to identify diagnostic and prognostic biomarkers in inflammatory bowel disease (IBD). METHODS: We conducted a prospective case-control study in an inception cohort of 552 patients (328 IBD, 224 non-IBD), profiling proteins recruited across 6 centres. Treatment escalation was characterised by the need for biological agents or surgery after initial disease remission. Nested leave-one-out cross validation was used to examine the performance of diagnostic and prognostic proteins. RESULTS: A total of 66 serum proteins differentiated IBD from symptomatic non-IBD controls including MMP-12 (Holm adjusted p=4.1×10 -23 ) and OSM (p=3.7×10 -16). Nine of these proteins associate with cis- germline variation (59 independent SNPs). Fifteen proteins, all members of TNF independent pathways including IL-1 and OSM predicted escalation, over a median follow-up of 518 (IQR 224-756) days. Nested cross-validation of the entire data set allows characterisation of 5-protein-models (96% comprising five core proteins ITGAV, EpCAM, IL18, SLAMF7, and IL8) which define a high-risk subgroup in IBD (HR 3.90, CI: 2.43-6.26), or allows distinct 2, and 3 protein models for UC and CD respectively. CONCLUSION: We have characterised a simple oligo-protein panel that has the potential to identify IBD from symptomatic controls and to predict future disease course. Further prospective work is required to validate our findings.
- Published
- 2021
- Full Text
- View/download PDF
206. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease : results from nationwide Swedish registers
- Author
-
Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, Halfvarson, Jonas, Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, and Halfvarson, Jonas
- Abstract
BACKGROUND: Comparisons of second-line anti-tumour necrosis factor (TNF) agents and vedolizumab are sparse. AIM: To evaluate the effectiveness of anti-TNF agents compared to vedolizumab as second-line biologics in inflammatory bowel disease (IBD). METHODS: A propensity score-matched cohort was created using Swedish nationwide registers. Patients with Crohn's disease or ulcerative colitis, exposed to first-line anti-TNF treatment, who initiated a second anti-TNF agent or vedolizumab in 2014-2016 (N = 1363) were included. The primary outcome was drug survival at 12 months. Secondarily, we assessed survival without IBD-related hospitalisation, IBD-related surgery, antibiotics, or hospitalisation because of infection, and also corticosteroid exposure. RESULTS: After 1:1 propensity score matching, 400 patients (Crohn's disease, N = 198; ulcerative colitis, N = 202) remained. For Crohn's disease, drug survival was 73% in the vedolizumab group vs 74% in the anti-TNF group (difference: 1 percentage point; 95% confidence interval [CI]:-11-13; P = 0.87). Survival without IBD-related hospitalisation (82% vs 88%), surgery (82% vs 89%), antibiotics (65% vs 71%), hospitalisation due to infection (95% vs 88%) and corticosteroids (58% vs 48%) were not statistically significantly different between groups. For ulcerative colitis, drug survival was 69% in the vedolizumab group vs 62% in the anti-TNF group (difference: -7 percentage points; 95% CI: -20 to 6; P = 0.30). Vedolizumab-treated patients had lower survival without IBD-related hospitalisation (82% vs 93%, P = 0.02). Survival without colectomy (93% vs 97%), antibiotics (81% vs 70%), hospitalisation due to infection (92% vs 92%) and corticosteroids (58% vs 48%) were not statistically significantly different. CONCLUSIONS: Based on Swedish clinical practice, the effectiveness and safety of second-line anti-TNF and vedolizumab at 12 months appeared largely similar., Funding Agency:Takeda Pharma AB IISR-2017-101937
- Published
- 2021
- Full Text
- View/download PDF
207. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
- Author
-
Reinisch, Walter, Gecse, Krisztina, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Peyrin-Biroulet, Laurent, Rogler, Gerhard, Schreiber, Stefan, Danese, Silvio, Reinisch, Walter, Gecse, Krisztina, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Peyrin-Biroulet, Laurent, Rogler, Gerhard, Schreiber, Stefan, and Danese, Silvio
- Abstract
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation of objective signs of inflammation, including endoscopic remission. Even though these agents are widely used for the treatment of moderate to severe CD, heterogeneity still exists in translating evidence-based guidelines on the use of anti-TNF agents into actual treatment algorithms in CD. This might be due to several reasons including disparities in health expenditure policies; lack of harmonization between countries; and variations in assessment of disease severity, use of disease monitoring tools, or application of treatment targets by physicians. With the advent of biosimilars, patent-free versions of reference biologics are now available to minimize health inequalities in drug availability. In this context, this article aims to provide practical clinical guidance for the use of infliximab and adalimumab biosimilars in patients with moderate to severe CD by outlining different clinical scenarios that patients may encounter during their treatment journey., Funding Agency:Sandoz, a Novartis division
- Published
- 2021
- Full Text
- View/download PDF
208. Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells
- Author
-
Mazzurana, Luca, Bonfiglio, Ferdinando, Forkel, Marianne, D'Amato, Mauro, Halfvarson, Jonas, Mjösberg, Jenny, Mazzurana, Luca, Bonfiglio, Ferdinando, Forkel, Marianne, D'Amato, Mauro, Halfvarson, Jonas, and Mjösberg, Jenny
- Abstract
BACKGROUND: Inflammatory bowel disease (IBD) is associated with disturbed mucosal innate lymphoid cell (ILC) composition, which is correlated to the degree of intestinal inflammation. However, it remains unclear whether circulating ILCs are dysregulated in patients with IBD. METHODS: Blood samples from 53 patients with Crohn's disease (CD), 43 patients with ulcerative colitis (UC), and 45 healthy control subjects (HC) were analyzed by flow cytometry for markers of ILC subsets (ILC1, ILC2, and ILC precursors [ILCp]) and selected IBD-relevant proteins, as predicted by previous genome-wide association studies. A dimensionality reduction approach to analyzing the data was used to characterize circulating ILCs. RESULTS: The frequency of ILCp expressing the ILC3 activation markers NKp44 and CD56 was increased in CD versus HC and UC (NKp44) or in CD versus HC (CD56), whereas the CD45RA+ ILCp were reduced in CD versus UC. Furthermore, the activation marker HLA-DR was increased on ILC1 and ILC2 in CD versus HC. Interestingly, the IBD-related protein SLAMF1 was upregulated on ILC2 from both CD and UC samples as compared with HC samples. In active CD, SLAMF1+ ILC2 frequency was negatively correlated with disease severity (Harvey-Bradshaw index). The characterization of SLAMF1+ ILC2 revealed a higher expression of the ILC2 markers CRTH2, CD161, and GATA3 as compared with SLAMF1- ILC2. CONCLUSIONS: In line with the systemic nature of CD inflammation, our findings point toward the activation of ILCs in the blood of patients with CD. Furthermore, in active CD, circulating SLAMF1+ ILC2 are increased in patients with less active disease, introducing SLAMF1+ ILC2 as interesting therapeutic targets deserving further exploration., Funding Agency:Örebro University Hospital Research Foundation OLL-409871
- Published
- 2021
- Full Text
- View/download PDF
209. Women's earnings are more affected by inflammatory bowel disease than men's : a register-based Swedish cohort study
- Author
-
Everhov, Åsa H., Bruze, Gustaf, Söderling, Jonas, Askling, Johan, Halfvarson, Jonas, Westberg, Karin, Malmborg, Petter, Nordenvall, Caroline, Ludvigsson, Jonas F., Olén, Ola, Everhov, Åsa H., Bruze, Gustaf, Söderling, Jonas, Askling, Johan, Halfvarson, Jonas, Westberg, Karin, Malmborg, Petter, Nordenvall, Caroline, Ludvigsson, Jonas F., and Olén, Ola
- Abstract
BACKGROUND/AIM: Patients with inflammatory bowel disease (IBD) have more work disability than the general population. We aimed to estimate the monetary cost of IBD for the individual through assessment of earnings in relation to diagnosis. METHODS: Through linkage of national registers we identified patients aged 30-55 years at first IBD diagnosis in Sweden 2002-2011, and same-sex IBD-free siblings. We estimated taxable earnings and disposable income from 5 years before to 5 years after diagnosis. RESULTS: The 5,961 patients (27% Crohn's disease, 68% ulcerative colitis, 4.3% IBD unclassified) had similar taxable earnings as their 7,810 siblings until the year of diagnosis, when earnings decreased and remained lower than in siblings during follow-up. The adjusted difference in earnings over the entire 5-year period after diagnosis was -5% (-8,212€; 95%CI: -11,458 to-4,967). The difference was larger in women than in men, and larger in Crohn's disease than in ulcerative colitis. When stratifying for sex and IBD subtype and comparing earnings during each year of follow-up, the median annual earnings were lower in women with Crohn's disease and ulcerative colitis than in their sisters during all years of follow-up, whereas the men had similar annual taxable earnings as their brothers. The disposable income was similar between patients and siblings during the investigated time period. CONCLUSION: From the year of diagnosis and at least 5 years onwards, patients with IBD had 5% lower earnings than siblings, mainly explained by differences between women with IBD and their sisters. However, there were no differences in disposable income., Funding Agencies:Bengt Ihre Research Foundation Strategic Research Area Epidemiology programme at the Karolinska Institutet
- Published
- 2021
- Full Text
- View/download PDF
210. Reply
- Author
-
Hirten, Robert P., Lakatos, Peter L., Halfvarson, Jonas, Colombel, Jean Frederic, Hirten, Robert P., Lakatos, Peter L., Halfvarson, Jonas, and Colombel, Jean Frederic
- Published
- 2021
- Full Text
- View/download PDF
211. Inflammatory bowel disease and risk of severe COVID-19 : A nationwide population-based cohort study in Sweden
- Author
-
Ludvigsson, Jonas F., Axelrad, Jordan, Halfvarson, Jonas, Khalili, Hamed, Larsson, Emma, Lochhead, Paul, Roelstraete, Bjorn, Simon, Tracey G., Söderling, Jonas, Olén, Ola, Ludvigsson, Jonas F., Axelrad, Jordan, Halfvarson, Jonas, Khalili, Hamed, Larsson, Emma, Lochhead, Paul, Roelstraete, Bjorn, Simon, Tracey G., Söderling, Jonas, and Olén, Ola
- Abstract
BACKGROUND: There are concerns that individuals with chronic immune-mediated diseases are at increased risk of COVID-19 and related severe adverse outcome, including intensive care admission or death. We aimed to explore the absolute and relative risk of severe COVID-19 in inflammatory bowel disease (IBD). METHODS: This population-based cohort study used nationwide registers in Sweden, with 67,292 individuals with a diagnosis of IBD 1969-2017 (Crohn's disease, n = 21,599; ulcerative colitis: n = 43,622; IBD-unclassified: n = 2071) and alive on 1 February 2020. Patients with IBD were matched to up to five controls from the general population (n = 297,910). Cox regression estimated hazard ratios (HRs) for (i) hospital admission with laboratory-confirmed COVID-19 as the primary diagnosis, and (ii) severe COVID-19 (composite outcome consisting of (a) COVID-19 intensive care admission, or (b) death from COVID-19 or (c) death within 30 days of COVID-19 hospital admission), were calculated. Analyses were conditioned on age, sex, calendar period, and county and adjusted for other comorbidities. RESULTS: Between 1 February and 31 July 2020, 179 (0.27%) IBD patients and 500 (0.17%) general population controls were admitted to hospital with COVID-19 (adjusted HR [aHR] = 1.43; 95% CI = 1.19-1.72). The corresponding numbers for severe COVID-19 was 65 (0.10%) and 183 (0.06%; aHR = 1.11; 95% CI = 0.81-1.52). Adjusted HRs were similar in Crohn's disease and ulcerative colitis. In a propensity score-matched model taking comorbidity into account until 2016, the increased risk for COVID-19 hospital admission remained (aHR = 1.32; 1.12-1.56), but there was no increased risk of severe COVID-19 (aHR = 1.12; 0.85-1.47). CONCLUSIONS: While individuals with IBD were more likely to be admitted to hospital for COVID-19 than the general population, the risk of severe COVID-19 was not higher., Funding Agency:Karolinska Institutet
- Published
- 2021
- Full Text
- View/download PDF
212. Editorial : anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply
- Author
-
Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, Halfvarson, Jonas, Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, and Halfvarson, Jonas
- Published
- 2021
- Full Text
- View/download PDF
213. Results of the Seventh Scientific Workshop of ECCO : Precision medicine in IBD- prediction and prevention of inflammatory bowel disease
- Author
-
Torres, Joana, Halfvarson, Jonas, Rodríguez-Lago, Iago, Hedin, Charlotte R. H., Jess, Tine, Dubinsky, Marla, Croitoru, Kenneth, Colombel, Jean-Frédéric, Verstockt, Bram, Fiocchi, Claudio, Scharl, Michael, Torres, Joana, Halfvarson, Jonas, Rodríguez-Lago, Iago, Hedin, Charlotte R. H., Jess, Tine, Dubinsky, Marla, Croitoru, Kenneth, Colombel, Jean-Frédéric, Verstockt, Bram, Fiocchi, Claudio, and Scharl, Michael
- Abstract
Inflammatory bowel disease [IBD] is a complex chronic disorder with no clear aetiology and no known cure. Despite recent advances in overall disease management and improved therapeutics, patients with IBD still experience a substantial burden. Furthermore, as the incidence continues to increase in developing areas of the world, it is expected that the burden of IBD to society will increase and exert tremendous pressure on healthcare systems worldwide. Therefore, new strategies to prevent the global increase of IBD are urgently required. Data are being progressively acquired on the period preceding disease diagnosis, which support the concept that IBD has a preclinical period that may reveal the triggers of disease and may be amenable to early intervention. Having a better knowledge of this preclinical period will increase the potential not only for improved understanding of disease pathogenesis and improved therapeutics, but also for disease prediction and prevention.
- Published
- 2021
- Full Text
- View/download PDF
214. Association between inflammatory bowel disease and psychiatric morbidity and suicide : A Swedish nationwide population-based cohort study with sibling comparisons
- Author
-
Ludvigsson, Jonas F., Olén, Ola, Larsson, Henrik, Halfvarson, Jonas, Almqvist, Catarina, Lichtenstein, Paul, Butwicka, Agnieszka, Ludvigsson, Jonas F., Olén, Ola, Larsson, Henrik, Halfvarson, Jonas, Almqvist, Catarina, Lichtenstein, Paul, and Butwicka, Agnieszka
- Abstract
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) is linked to psychiatric morbidity, but few studies have assessed general population comparators. We aimed to investigate the risk of psychiatric morbidity and suicide in adult-onset IBD patients. METHODS: Nationwide population-based cohort study in Sweden (1973-2013). We studied the risk of psychiatric disorders and suicide in 69,865 adult-onset IBD patients (ulcerative colitis, UC: n=43,557; Crohn's disease, CD: n=21,245; and IBD-unclassified: n=5063) compared to 3,472,913 general population references and 66,292 siblings. RESULTS: During a median follow-up of 11 years, we found 7,465 (10.7%) first psychiatric disorders in IBD (incidence rate, IR/1000 person-years 8.4) and 306,911 (9.9%) in the general population (IR 6.6), resulting in 1.8 extra psychiatric morbidity per 100 patients followed-up for 10 years and a hazard ratio (HR) of 1.3 (95% confidence interval, 95%CI=1.2-1.3). The highest risk of overall psychiatric morbidity was seen in the first year after IBD diagnosis (HR=1.4, 95%CI=1.2-1.6) and in patients with extraintestinal manifestations (HR=1.6, 95%CI=1.5-1.7). Psychiatric morbidity was more common in all IBD subtypes (HRs 1.3 to 1.5). An increased risk of suicide attempts was observed among all IBD types (HRs=1.2 to 1.4), whereas completed suicide was explicitly associated with CD (HR=1.5) and elderly-onset (diagnosed at the age of >60 years) IBD (HR=1.7). CONCLUSION: Adult-onset IBD was associated with an increased risk of psychiatric disorders and suicide attempts. Psychological follow-up should be provided to patients with IBD, especially those with extraintestinal manifestations and elderly-onset IBD. This follow-up should transpire within the first year after IBD diagnosis., Funding agencies:Karolinska Institutet, Strategic Research Program in Neuroscience [StratNeuro]Strategic Research Area Epidemiology programme at Karolinska InstitutetSwedish Research Council through the Swedish Initiative for Research on Microdata in the Social And Medical Sciences [SIMSAM] 340-2013-5867
- Published
- 2021
- Full Text
- View/download PDF
215. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice
- Author
-
Nguyen, Hang Thi Thu, Dalmasso, Guillaume, Torkvist, Leif, Halfvarson, Jonas, Yan, Yutao, Laroui, Hamed, Shmerling, Doron, Tallone, Tiziano, D'Amato, Mauro, Sitaraman, Shanthi V., and Merlin, Didier
- Subjects
Glycoproteins -- Physiological aspects -- Research ,Inflammation -- Risk factors -- Research ,Homeostasis -- Research ,Colitis -- Analysis -- Research -- Risk factors ,Health care industry - Abstract
Expression of the transmembrane glycoprotein CD98 (encoded by SLC3A2) is increased in intestinal inflammatory conditions, such as inflammatory bowel disease (IBD), and in various carcinomas, yet its pathogenetic role remains [...]
- Published
- 2011
- Full Text
- View/download PDF
216. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome
- Author
-
Wouters, Mira M, Lambrechts, Diether, Knapp, Michael, Cleynen, Isabelle, Whorwell, Peter, Agréus, Lars, Dlugosz, Aldona, Schmidt, Peter Thelin, Halfvarson, Jonas, Simrén, Magnus, Ohlsson, Bodil, Karling, Pontus, Van Wanrooy, Sander, Mondelaers, Stéphanie, Vermeire, Severine, Lindberg, Greger, Spiller, Robin, Dukes, George, DʼAmato, Mauro, and Boeckxstaens, Guy
- Published
- 2014
- Full Text
- View/download PDF
217. Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection
- Author
-
Björkqvist, Olle, primary, Rangel, Ignacio, additional, Serrander, Lena, additional, Magnusson, Cecilia, additional, Halfvarson, Jonas, additional, Norén, Torbjörn, additional, and Bergman-Jungeström, Malin, additional
- Published
- 2021
- Full Text
- View/download PDF
218. Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD. Authors' reply
- Author
-
Rundquist, Sara, primary, Sachs, Michael C, additional, Eriksson, Carl, additional, Olén, Ola, additional, Montgomery, Scott, additional, and Halfvarson, Jonas, additional
- Published
- 2021
- Full Text
- View/download PDF
219. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
- Author
-
Le Berre, Catherine, primary, Peyrin-Biroulet, Laurent, additional, Sandborn, William J., additional, Colombel, Jean-Frédéric, additional, Rubin, David, additional, Chowers, Yehuda, additional, Reinisch, Walter, additional, Schreiber, Stefan, additional, Allez, Matthieu, additional, D’Haens, Geert, additional, Ghosh, Subrata, additional, Koutroubakis, Ioannis E., additional, Gibson, Peter, additional, Halfvarson, Jonas, additional, Hart, Ailsa, additional, Kaser, Arthur, additional, Munkholm, Pia, additional, Kruis, Wolfgang, additional, Vermeire, Severine, additional, Loftus, Edward V., additional, Lukas, Milan, additional, Mantzaris, Gerassimos J., additional, O’Morain, Colm, additional, Panes, Julian, additional, Rogler, Gerhard, additional, Spinelli, Antonino, additional, Sands, Bruce E., additional, Ananthakrishnan, Aswhin N., additional, Ng, Siew C., additional, Sachar, David, additional, Travis, Simon, additional, Steinwurz, Flavio, additional, Turner, Dan, additional, Dulai, Parambir S., additional, Jairath, Vipul, additional, Dotan, Iris, additional, Abreu, Maria, additional, Panaccione, Remo, additional, and Danese, Silvio, additional
- Published
- 2021
- Full Text
- View/download PDF
220. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Prediction and Prevention of Inflammatory Bowel Disease
- Author
-
Torres, Joana, primary, Halfvarson, Jonas, additional, Rodríguez-Lago, Iago, additional, Hedin, Charlotte R H, additional, Jess, Tine, additional, Dubinsky, Marla, additional, Croitoru, Kenneth, additional, and Colombel, Jean-Frédéric, additional
- Published
- 2021
- Full Text
- View/download PDF
221. Inflammatory bowel disease and risk of severe COVID‐19: A nationwide population‐based cohort study in Sweden
- Author
-
Ludvigsson, Jonas F., primary, Axelrad, Jordan, additional, Halfvarson, Jonas, additional, Khalili, Hamed, additional, Larsson, Emma, additional, Lochhead, Paul, additional, Roelstraete, Bjorn, additional, Simon, Tracey G., additional, Söderling, Jonas, additional, and Olén, Ola, additional
- Published
- 2021
- Full Text
- View/download PDF
222. Association Between Inflammatory Bowel Disease and Psychiatric Morbidity and Suicide: A Swedish Nationwide Population-Based Cohort Study With Sibling Comparisons
- Author
-
Ludvigsson, Jonas F, primary, Olén, Ola, additional, Larsson, Henrik, additional, Halfvarson, Jonas, additional, Almqvist, Catarina, additional, Lichtenstein, Paul, additional, and Butwicka, Agnieszka, additional
- Published
- 2021
- Full Text
- View/download PDF
223. Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study
- Author
-
Erichsen, Rune, primary, Olén, Ola, additional, Sachs, Michael C., additional, Pedersen, Lars, additional, Halfvarson, Jonas, additional, Askling, Johan, additional, Ekbom, Anders, additional, Ludvigsson, Jonas F., additional, and Sørensen, Henrik Toft, additional
- Published
- 2021
- Full Text
- View/download PDF
224. Editorial: anti‐TNF agents against vedolizumab as a second‐line treatment? Not surprising tie game—authors’ reply
- Author
-
Rundquist, Sara, primary, Sachs, Michael C., additional, Eriksson, Carl, additional, Olén, Ola, additional, Montgomery, Scott, additional, and Halfvarson, Jonas, additional
- Published
- 2021
- Full Text
- View/download PDF
225. Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study
- Author
-
Everhov,à sa, Sachs,Michael, Ludvigsson,Jonas, Khalili,Hamed, Askling,Johan, Neovius,Martin, Myrelid,Pär, Halfvarson,Jonas, Nordenvall,Caroline, Söderling,Jonas, and Olen,Ola
- Subjects
Clinical Epidemiology - Abstract
Åsa H Everhov, 1, 2 Michael C Sachs, 2 Jonas F Ludvigsson, 3, 4 Hamed Khalili, 2, 5 Johan Askling, 2 Martin Neovius, 2 Pär Myrelid, 6, 7 Jonas Halfvarson, 8 Caroline Nordenvall, 9, 10 Jonas Söderling, 2 Ola Olén 1, 2, 11on behalf of the SWIBREG study group 1Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; 2Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 4Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; 5Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 6Division of Surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden; 7Department of Surgery, County Council of Östergötland Linköping, Linköping, Sweden; 8Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; 9Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; 10Center for Digestive Disease, Division of Coloproctology, Karolinska University Hospital, Stockholm, Sweden; 11Department of Pediatric Gastroenterology and Nutrition, Sachs’ Children and Youth Hospital, Stockholm, SwedenCorrespondence: Åsa H EverhovDepartment of Surgery, Stockholm South General Hospital, Stockholm SE 118 61, SwedenTel +46 8 616 2349Email asa.hallqvist-everhov@ki.sePurpose: Patients with Crohn’s disease have increased work loss. We aimed to describe changes in work ability in relation to pharmacological and surgical treatments.Patients and Methods: We linked data from the Swedish National Patient Register, The Swedish Quality Register for Inflammatory Bowel Disease SWIBREG, The Prescribed Drug Register, The Longitudinal Integrated Database for Health Insurance and Labour Market Studies, and the Social Insurance Database. We identified working-age (19– 59 years) patients with incident Crohn’s disease 2006– 2013 and population comparator subjects matched by sex, birth year, region, and education level. We assessed the number of lost workdays due to sick leave and disability pension before and after treatments.Results: Of 3956 patients (median age 34 years, 51% women), 39% were treated with aminosalicylates, 52% with immunomodulators, 22% with TNF inhibitors, and 18% with intestinal surgery during a median follow-up of 5.3 years. Most patients had no work loss during the study period (median=0 days). For all treatments, the mean number of lost workdays increased during the months before treatment initiation, peaked during the first month of treatment and decreased thereafter, and was heavily influenced by sociodemographic factors and amount of work loss before first Crohn’s disease diagnosis. The mean increase in work loss days compared to pre-therapeutic level was ∼ 3 days during the first month of treatment for all pharmacological therapies and 11 days for intestinal surgery. Three months after treatment initiation, 88% of patients treated surgically and 90– 92% of patients treated pharmacologically had the same amount of work loss as before treatment start. Median time to return to work was 2 months for all treatments.Conclusion: In this regular clinical setting, patients treated surgically had more lost workdays than patients treated pharmacologically, but return to work was similar between all treatments.Keywords: inflammatory bowel disease, sick leave, disability pension, TNF inhibitor, aminosalicylate, immunomodulator
- Published
- 2020
226. sj-pdf-1-ueg-10.1177_2050640620945949 - Supplemental material for The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study
- Author
-
Burisch, Johan, Bergemalm, Daniel, Halfvarson, Jonas, Domislovic, Viktor, Zeljko Krznaric, Goldis, Adrian, Dahlerup, Jens F, Oksanen, Pia, Collin, Pekka, Castro, Luisa De, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, D'Incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Misra, Ravi, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Gatt, Kelly, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Andersen, Karina W, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Shaji Sebastian, Barros, Luisa, Magro, Fernando, Jóngerð MM Midjord, Nielsen, Kári R, Salupere, Riina, Kievit, Hendrika AL, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-Rousseau, Corinne, Kaimakliotis, Ioannis P, Schwartz, Doron, Odes, Selwyn, Laszlo Lakatos, Lakatos, Peter L, Langholz, Ebbe, and Munkholm, Pia
- Subjects
FOS: Clinical medicine ,FOS: Biological sciences ,111199 Nutrition and Dietetics not elsewhere classified ,FOS: Health sciences ,110308 Geriatrics and Gerontology ,69999 Biological Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-pdf-1-ueg-10.1177_2050640620945949 for The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study by Johan Burisch, Daniel Bergemalm, Jonas Halfvarson, Viktor Domislovic, Zeljko Krznaric, Adrian Goldis, Jens F Dahlerup, Pia Oksanen, Pekka Collin, Luisa de Castro, Vicent Hernandez, Svetlana Turcan, Elena Belousova, Renata D'Incà, Alessandro Sartini, Daniela Valpiani, Martina Giannotta, Ravi Misra, Naila Arebi, Dana Duricova, Martin Bortlik, Kelly Gatt, Pierre Ellul, Natalia Pedersen, Jens Kjeldsen, Karina W Andersen, Vibeke Andersen, Konstantinos H Katsanos, Dimitrios K Christodoulou, Shaji Sebastian, Luisa Barros, Fernando Magro, Jóngerð MM Midjord, Kári R Nielsen, Riina Salupere, Hendrika AL Kievit, Gediminas Kiudelis, Juozas Kupčinskas, Mathurin Fumery, Corinne Gower-Rousseau, Ioannis P Kaimakliotis, Doron Schwartz, Selwyn Odes, Laszlo Lakatos, Peter L Lakatos, Ebbe Langholz, Pia Munkholm and for the Epi-IBD group in United European Gastroenterology Journal
- Published
- 2020
- Full Text
- View/download PDF
227. Mo1775 INFLAMMATORY BOWEL DISEASE AND RISK OF COLORECTAL POLYPS: A NATIONWIDE POPULATION-BASED COHORT STUDY FROM SWEDEN
- Author
-
Axelrad, Jordan E., Olen, Ola, Soderling, Jonas, Roelstraete, Bjorn, Khalili, Hamed, Song, Mingyang, Faye, Adam S., Eberhardson, Michael, Halfvarson, Jonas, and Ludvigsson, Jonas F.
- Published
- 2023
- Full Text
- View/download PDF
228. Mo1768 LONG-TERM RISK OF STROKE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLING-CONTROLLED COHORT STUDY 1965-2019
- Author
-
Sun, Jiangwei, Halfvarson, Jonas, Appelros, Peter, Bergman, David, Ebrahimi, Fahim, Roelstraete, Bjorn, Olen, Ola, and Ludvigsson, Jonas F.
- Published
- 2023
- Full Text
- View/download PDF
229. Su1759 IDENTIFICATION AND VALIDATION OF A LIPIDOMIC SIGNATURE AS A NOVEL DIAGNOSTIC BIOMARKER OF PEDIATRIC INFLAMMATORY BOWEL DISEASE
- Author
-
Salihovic, Samira, Nyström, Niklas, Mathisen, Charlotte B., Andersen, Svend, Olbj⊘rn, Christine, Perminow, G⊘ri, Opheim, Randi, Detlie, Trond Espen, Huppertz-Hauss, Gert, Bazov, Igor, Kruse, Robert, Lindqvist, Carl Mårten, Hedin, Charlotte R., Carlson, Marie, Ohman, Lena, Magnusson, Maria K., Keita, Åsa V., Söderholm, Johan D., D'Amato, Mauro, Oresic, Matej, Repsilber, Dirk, Hyötyläinen, Tuulia, Hoivik, Marte L., and Halfvarson, Jonas
- Published
- 2023
- Full Text
- View/download PDF
230. Su1757 A NOVEL DIAGNOSTIC SERUM PROTEIN SIGNATURE FOR PEDIATRIC INFLAMMATORY BOWEL DISEASE: A DISCOVERY AND VALIDATION STUDY IN TWO INDEPENDENT INCEPTION COHORTS
- Author
-
Mathisen, Charlotte B., Bazov, Igor, Nyström, Niklas, Andersen, Svend, Olbj⊘rn, Christine, Perminow, G⊘ri, Kristensen, Vendel, Opheim, Randi, Ricanek, Petr, D'Amato, Mauro, Carlson, Marie, Hedin, Charlotte R., Keita, Åsa V., Kruse, Robert, Lindqvist, Carl Mårten, Magnusson, Maria K., Salihovic, Samira, Söderholm, Johan D., Ohman, Lena, Repsilber, Dirk, H⊘ivik, Marte Lie, and Halfvarson, Jonas
- Published
- 2023
- Full Text
- View/download PDF
231. Su1758 A NOVEL SERUM PROTEIN SIGNATURE AS BIOMARKER FOR INFLAMMATORY BOWEL DISEASE: A DIAGNOSTIC PERFORMANCE AND PREDICTION MODELLING STUDY USING DATA FROM TWO INDEPENDENT INCEPTION COHORTS
- Author
-
Bazov, Igor, Kruse, Robert, Daniel, Bergemalm, Eriksson, Carl, Hedin, Charlotte R., Carlson, Marie, van Nieuwenhoven, Michiel, Keita, Åsa V., Magnusson, Maria K., Almer, Sven, Strid, Hans, Mathisen, Charlotte B., Bengtson, May-Bente, Aaabrekke, Tone Bergene, Medhus, Asle W., Detlie, Trond Espen, Frigstad, Svein Oskar, Huppertz-Hauss, Gert, Opheim, Randi, Ricanek, Petr, Kristensen, Vendel, Salihovic, Samira, D'Amato, Mauro, Ohman, Lena, Söderholm, Johan D., Lindqvist, Carl Mårten, Repsilber, Dirk, H⊘ivik, Marte Lie, and Halfvarson, Jonas
- Published
- 2023
- Full Text
- View/download PDF
232. Sa1818 LONG-TERM RISK OF ARRHYTHMIAS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLINGCONTROLED COHORT STUDY 1965-2019
- Author
-
Sun, Jiangwei, Roelstraete, Bjorn, Svennberg, Emma, Halfvarson, Jonas, Sundstrom, Johan, Forss, Anders, Olen, Ola, and Ludvigsson, Jonas F.
- Published
- 2023
- Full Text
- View/download PDF
233. Sa1771 ATHEROSCLEROSIS AS A RISK FACTOR FOR IBD; A POPULATION-BASED CASE-CONTROL STUDY
- Author
-
Faye, Adam S., Axelrad, Jordan E., Sun, Jiangwei, Halfvarson, Jonas, Sundstrom, Johan, Soderling, Jonas, Olen, Ola, and Ludvigsson, Jonas F.
- Published
- 2023
- Full Text
- View/download PDF
234. 690 STATIN USE AND RISK OF COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- Author
-
Sun, Jiangwei, Halfvarson, Jonas, Bergman, David, Ebrahimi, Fahim, Roelstraete, Bjorn, Olen, Ola, and Ludvigsson, Jonas F.
- Published
- 2023
- Full Text
- View/download PDF
235. Fine-mapping inflammatory bowel disease loci to single-variant resolution
- Author
-
Huang, Hailiang, Fang, Ming, Jostins, Luke, Umievi Mirkov, Maa, Boucher, Gabrielle, Anderson, Carl A., Andersen, Vibeke, Cleynen, Isabelle, Cortes, Adrian, Crins, Franois, DAmato, Mauro, Deffontaine, Valrie, Dmitrieva, Julia, Docampo, Elisa, Elansary, Mahmoud, Farh, Kyle Kai-How, Franke, Andre, Gori, Ann-Stephan, Goyette, Philippe, Halfvarson, Jonas, Haritunians, Talin, Knight, Jo, Lawrance, Ian C., Lees, Charlie W., Louis, Edouard, Mariman, Rob, Meuwissen, Theo, Mni, Myriam, Momozawa, Yukihide, Parkes, Miles, Spain, Sarah L., Thtre, Emilie, Trynka, Gosia, Satsangi, Jack, van Sommeren, Suzanne, Vermeire, Severine, Xavier, Ramnik J., Weersma, Rinse K., Duerr, Richard H., Mathew, Christopher G., Rioux, John D., McGovern, Dermot P. B., Cho, Judy H., Georges, Michel, Daly, Mark J., and Barrett, Jeffrey C.
- Subjects
Inflammatory bowel diseases -- Genetic aspects ,Quantitative trait loci -- Health aspects ,Genetic variation -- Health aspects ,Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
Inflammatory bowel diseases are chronic gastrointestinal inflammatory disorders that affect millions of people worldwide. Genome-wide association studies have identified 200 inflammatory bowel disease-associated loci, but few have been conclusively resolved to specific functional variants. Here we report fine-mapping of 94 inflammatory bowel disease loci using high-density genotyping in 67,852 individuals. We pinpoint 18 associations to a single causal variant with greater than 95% certainty, and an additional 27 associations to a single variant with greater than 50% certainty. These 45 variants are significantly enriched for protein-coding changes (n=13), direct disruption of transcription-factor binding sites (n=3), and tissue-specific epigenetic marks (n=10), with the last category showing enrichment in specific immune cells among associations stronger in Crohns disease and in gut mucosa among associations stronger in ulcerative colitis. The results of this study suggest that high-resolution fine-mapping in large samples can convert many discoveries from genome-wide association studies into statistically convincing causal variants, providing a powerful substrate for experimental elucidation of disease mechanisms., Author(s): Hailiang Huang (corresponding author) [1, 2]; Ming Fang [3, 4]; Luke Jostins [5, 6]; Maa Umievi Mirkov [7]; Gabrielle Boucher [8]; Carl A. Anderson [7]; Vibeke Andersen [9, 10]; [...]
- Published
- 2017
- Full Text
- View/download PDF
236. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease
- Author
-
Ungaro, Ryan C., Yzet, Clara, Bossuyt, Peter, Baert, Filip J., Vanasek, Thomas, D'Haens, Geert R., Joustra, Vincent Wilhelmus, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P., Hebuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollon, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M., Halfvarson, Jonas, Butler, James W., Petersson, Joel, Petralia, Francesca, Colombel, Jean-Frederic, Ungaro, Ryan C., Yzet, Clara, Bossuyt, Peter, Baert, Filip J., Vanasek, Thomas, D'Haens, Geert R., Joustra, Vincent Wilhelmus, Panaccione, Remo, Novacek, Gottfried, Reinisch, Walter, Armuzzi, Alessandro, Golovchenko, Oleksandr, Prymak, Olga, Goldis, Adrian, Travis, Simon P., Hebuterne, Xavier, Ferrante, Marc, Rogler, Gerhard, Fumery, Mathurin, Danese, Silvio, Rydzewska, Grazyna, Pariente, Benjamin, Hertervig, Erik, Stanciu, Carol, Serrero, Melanie, Diculescu, Mircea, Peyrin-Biroulet, Laurent, Laharie, David, Wright, John P., Gomollon, Fernando, Gubonina, Irina, Schreiber, Stefan, Motoya, Satoshi, Hellström, Per M., Halfvarson, Jonas, Butler, James W., Petersson, Joel, Petralia, Francesca, and Colombel, Jean-Frederic
- Abstract
BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 +/- 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P =.01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.070.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of diseas
- Published
- 2020
- Full Text
- View/download PDF
237. The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register
- Author
-
Shrestha, Sarita, Olén, Ola, Eriksson, Carl, Everhov, Åsa H., Myrelid, Pär, Visuri, Isabella, Ludvigsson, Jonas F., Schoultz, Ida, Montgomery, Scott, Sachs, Michael C., Halfvarson, Jonas, Olsson, Malin, Hjortswang, Henrik, Bengtsson, Jonas, Strid, Hans, Andersson, Marie, Jäghult, Susanna, Eberhardson, Michael, Nordenvall, Caroline, Björk, Jan, Fagerberg, Ulrika L., Rejler, Martin, Grip, Olof, Karling, Pontus, Block, Mattias, Angenete, Eva, Hellström, Per M., Gustavsson, Anders, Shrestha, Sarita, Olén, Ola, Eriksson, Carl, Everhov, Åsa H., Myrelid, Pär, Visuri, Isabella, Ludvigsson, Jonas F., Schoultz, Ida, Montgomery, Scott, Sachs, Michael C., Halfvarson, Jonas, Olsson, Malin, Hjortswang, Henrik, Bengtsson, Jonas, Strid, Hans, Andersson, Marie, Jäghult, Susanna, Eberhardson, Michael, Nordenvall, Caroline, Björk, Jan, Fagerberg, Ulrika L., Rejler, Martin, Grip, Olof, Karling, Pontus, Block, Mattias, Angenete, Eva, Hellström, Per M., and Gustavsson, Anders
- Abstract
Introduction: Whether data on International Classification of Diseases (ICD)-codes from the Swedish National Patient Register (NPR) correctly correspond to subtypes of inflammatory bowel disease (IBD) and phenotypes of the Montreal classification scheme among patients with prevalent disease is unknown. Materials and methods: We obtained information on IBD subtypes and phenotypes from the medical records of 1403 patients with known IBD who underwent biological treatment at ten Swedish hospitals and retrieved information on their IBD-associated diagnostic codes from the NPR. We used previously described algorithms to define IBD subtypes and phenotypes. Finally, we compared these register-generated subtypes and phenotypes with the corresponding information from the medical records and calculated positive predictive values (PPV) with 95% confidence intervals. Results: Among patients with clinically confirmed disease and diagnostic listings of IBD in the NPR (N = 1401), the PPV was 97 (96-99)% for Crohn's disease, 98 (97-100)% for ulcerative colitis, and 8 (4-11)% for IBD-unclassified. The overall accuracy for age at diagnosis was 95% (when defined as A1, A2, or A3). Examining the validity of codes representing disease phenotype, the PPV was 36 (32-40)% for colonic Crohn's disease (L2), 61 (56-65)% for non-stricturing/non-penetrating Crohn's disease behaviour (B1) and 83 (78-87)% for perianal disease. Correspondingly, the PPV was 80 (71-89)% for proctitis (E1)/left-sided colitis (E2) in ulcerative colitis. Conclusions: Among people with known IBD, the NPR is a reliable source of data to classify most subtypes of prevalent IBD, even though misclassification commonly occurred in Crohn's disease location and behaviour and also among IBD-unclassified patients.
- Published
- 2020
- Full Text
- View/download PDF
238. Work Loss in Relation to Pharmacological and Surgical Treatment for Crohns Disease: A Population-Based Cohort Study
- Author
-
Everhov, Asa, Sachs, Michael, Ludvigsson, Jonas, Khalili, Hamed, Askling, Johan, Neovius, Martin, Myrelid, Pär, Halfvarson, Jonas, Nordenvall, Caroline, Soderling, Jonas, Olen, Ola, Everhov, Asa, Sachs, Michael, Ludvigsson, Jonas, Khalili, Hamed, Askling, Johan, Neovius, Martin, Myrelid, Pär, Halfvarson, Jonas, Nordenvall, Caroline, Soderling, Jonas, and Olen, Ola
- Abstract
Purpose: Patients with Crohns disease have increased work loss. We aimed to describe changes in work ability in relation to pharmacological and surgical treatments. Patients and Methods: We linked data from the Swedish National Patient Register, The Swedish Quality Register for Inflammatory Bowel Disease SWIBREG, The Prescribed Drug Register, The Longitudinal Integrated Database for Health Insurance and Labour Market Studies, and the Social Insurance Database. We identified working-age (19-59 years) patients with incident Crohns disease 2006-2013 and population comparator subjects matched by sex, birth year, region, and education level. We assessed the number of lost workdays due to sick leave and disability pension before and after treatments. Results: Of 3956 patients (median age 34 years, 51% women), 39% were treated with aminosalicylates, 52% with immunomodulators, 22% with TNF inhibitors, and 18% with intestinal surgery during a median follow-up of 5.3 years. Most patients had no work loss during the study period (median=0 days). For all treatments, the mean number of lost workdays increased during the months before treatment initiation, peaked during the first month of treatment and decreased thereafter, and was heavily influenced by sociodemographic factors and amount of work loss before first Crohns disease diagnosis. The mean increase in work loss days compared to pre-therapeutic level was similar to 3 days during the first month of treatment for all pharmacological therapies and 11 days for intestinal surgery. Three months after treatment initiation, 88% of patients treated surgically and 90-92% of patients treated pharmacologically had the same amount of work loss as before treatment start. Median time to return to work was 2 months for all treatments. Conclusion: In this regular clinical setting, patients treated surgically had more lost workdays than patients treated pharmacologically, but return to work was similar between all treatments., Funding Agencies|Karolinska Institutet (KI SOS); Bengt Ihre Research Foundation; Bengt Ihre Research Fellowship; Swedish Research CouncilSwedish Research Council; Swedish Cancer SocietySwedish Cancer Society; Swedish Foundation for Strategic ResearchSwedish Foundation for Strategic Research; Stockholm County Council (ALF)Stockholm County Council; Ferring
- Published
- 2020
- Full Text
- View/download PDF
239. Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry
- Author
-
Salihovic, Samira, Dickens, Alex M., Schoultz, Ida, Fart, Frida, Sinisalu, Lisanna, Lindeman, Tuomas, Halfvarson, Jonas, Oresic, Matej, Hyötyläinen, Tuulia, Salihovic, Samira, Dickens, Alex M., Schoultz, Ida, Fart, Frida, Sinisalu, Lisanna, Lindeman, Tuomas, Halfvarson, Jonas, Oresic, Matej, and Hyötyläinen, Tuulia
- Abstract
There is evidence of a positive association between per- and polyfluoroalkyl substances (PFASs) and cholesterol levels in human plasma, which may be due to common reabsorption of PFASs and bile acids (BAs) in the gut. Here we report development and validation of a method that allows simultaneous, quantitative determination of PFASs and BAs in plasma, using 150 μL or 20 μL of sample. The method involves protein precipitation using 96-well plates. The instrumental analysis was performed with ultra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS), using reverse-phase chromatography, with the ion source operated in negative electrospray mode. The mass spectrometry analysis was carried out using multiple reaction monitoring mode. The method proved to be sensitive, robust, and with sufficient linear range to allow reliable determination of both PFASs and BAs. The method detection limits were between 0.01 and 0.06 ng mL-1 for PFASs and between 0.002 and 0.152 ng mL-1 for BAs, with the exception of glycochenodeoxycholic acid (0.56 ng mL-1). The PFAS measured showed excellent agreement with certified plasma PFAS concentrations in NIST SRM 1957 reference serum. The method was tested on serum samples from 20 healthy individuals. In this proof-of-concept study, we identified significant associations between plasma PFAS and BA levels, which suggests that PFAS may alter the synthesis and/or uptake of BAs.
- Published
- 2020
- Full Text
- View/download PDF
240. Global variability of the human IgG glycome
- Author
-
Stambuk, Jerko, Nakic, Natali, Vuckovic, Frano, Pucic-Bakovic, Maja, Razdorov, Genadij, Trbojevic-Akmacic, Irena, Novokmet, Mislav, Keser, Toma, Vilaj, Marija, Stambuk, Tamara, Gudelj, Ivan, Simurina, Mirna, Song, Manshu, Wang, Hao, Salihovic, Marijana Pericic, Campbell, Harry, Rudan, Igor, Kolcic, Ivana, Eller, Leigh Anne, McKeigue, Paul, Robb, Merlin L., Halfvarson, Jonas, Kurtoglu, Metin, Annese, Vito, Skaric-Juric, Tatjana, Molokhia, Mariam, Polasek, Ozren, Hayward, Caroline, Kibuuka, Hannah, Thaqi, Kujtim, Primorac, Dragan, Geieger, Christian, Nitayaphan, Sorachai, Spector, Tim, Wang, Youxin, Tillin, Therese, Chaturvedi, Nish, Wilson, James F., Schanfield, Moses, Filipenko, Maxim, Wang, Wei, Lauc, Gordan, Stambuk, Jerko, Nakic, Natali, Vuckovic, Frano, Pucic-Bakovic, Maja, Razdorov, Genadij, Trbojevic-Akmacic, Irena, Novokmet, Mislav, Keser, Toma, Vilaj, Marija, Stambuk, Tamara, Gudelj, Ivan, Simurina, Mirna, Song, Manshu, Wang, Hao, Salihovic, Marijana Pericic, Campbell, Harry, Rudan, Igor, Kolcic, Ivana, Eller, Leigh Anne, McKeigue, Paul, Robb, Merlin L., Halfvarson, Jonas, Kurtoglu, Metin, Annese, Vito, Skaric-Juric, Tatjana, Molokhia, Mariam, Polasek, Ozren, Hayward, Caroline, Kibuuka, Hannah, Thaqi, Kujtim, Primorac, Dragan, Geieger, Christian, Nitayaphan, Sorachai, Spector, Tim, Wang, Youxin, Tillin, Therese, Chaturvedi, Nish, Wilson, James F., Schanfield, Moses, Filipenko, Maxim, Wang, Wei, and Lauc, Gordan
- Abstract
Immunoglobulin G (IgG) is the most abundant serum antibody which structural characteristics and effector functions are modulated through the attachment of various sugar moieties called glycans. Composition of the IgG N-glycome changes with age of an individual and in different diseases. Variability of IgG glycosylation within a population is well studied and is known to be affected by both genetic and environmental factors. However, global inter-population differences in IgG glycosylation have never been properly addressed. Here we present population-specific N-glycosylation patterns of IgG, analyzed in 5 different populations totaling 10,482 IgG glycomes, and of IgG’s fragment crystallizable region (Fc), analyzed in 2,579 samples from 27 populations sampled across the world. Country of residence associated with many N-glycan features and the strongest association was with monogalactosylation where it explained 38% of variability. IgG monogalactosylation strongly correlated with the development level of a country, defined by United Nations health and socioeconomic development indicators, and with the expected lifespan. Subjects from developing countries had low levels of IgG galactosylation, characteristic for inflammation and ageing. Our results suggest that citizens of developing countries may be exposed to environmental factors that can cause low-grade chronic inflammation and the apparent increase in biological age.
- Published
- 2020
241. Depletion of erythropoietic miR-486-5p and miR-451a improves detectability of rare microRNAs in peripheral blood-derived small RNA sequencing libraries
- Author
-
Juzenas, Simonas, Lindqvist, Carl Mårten, Ito, Go, Dolshanskaya, Yewgenia, Halfvarson, Jonas, Franke, Andre, Hemmrich-Stanisak, Georg, Juzenas, Simonas, Lindqvist, Carl Mårten, Ito, Go, Dolshanskaya, Yewgenia, Halfvarson, Jonas, Franke, Andre, and Hemmrich-Stanisak, Georg
- Abstract
Erythroid-specific miR-451a and miR-486-5p are two of the most dominant microRNAs (miRNAs) in human peripheral blood. In small RNA sequencing libraries, their overabundance reduces diversity as well as complexity and consequently causes negative effects such as missing detectability and inaccurate quantification of low abundant miRNAs. Here we present a simple, cost-effective and easy to implement hybridization-based method to deplete these two erythropoietic miRNAs from blood-derived RNA samples. By utilization of blocking oligonucleotides, this method provides a highly efficient and specific depletion of miR-486-5p and miR-451a, which leads to a considerable increase of measured expression as well as detectability of low abundant miRNA species. The blocking oligos are compatible with common 5′ ligation-dependent small RNA library preparation protocols, including commercially available kits, such as Illumina TruSeq and Perkin Elmer NEXTflex. Furthermore, the here described method and oligo design principle can be easily adapted to target many other miRNA molecules, depending on context and research question., lqaa008
- Published
- 2020
- Full Text
- View/download PDF
242. Correction to: The Future of Biosimilars : Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (vol 80, pg 99, 2020)
- Author
-
Kim, HoUng, Alten, Rieke, Avedano, Luisa, Dignass, Axel, Gomollón, Fernando, Greveson, Kay, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Lakatos, Péter L., Lee, JongHyuk, Makri, Souzi, Parker, Ben, Peyrin-Biroulet, Laurent, Schreiber, Stefan, Simoens, Steven, Westhovens, Rene, Danese, Silvio, Jeong, Ji Hoon, Kim, HoUng, Alten, Rieke, Avedano, Luisa, Dignass, Axel, Gomollón, Fernando, Greveson, Kay, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Lakatos, Péter L., Lee, JongHyuk, Makri, Souzi, Parker, Ben, Peyrin-Biroulet, Laurent, Schreiber, Stefan, Simoens, Steven, Westhovens, Rene, Danese, Silvio, and Jeong, Ji Hoon
- Abstract
The affiliation of the corresponding author Silvio Danese, which currently reads.
- Published
- 2020
- Full Text
- View/download PDF
243. Colorectal cancer in ulcerative colitis : a Scandinavian population-based cohort study
- Author
-
Olén, Ola, Erichsen, Rune, Sachs, Michael C., Pedersen, Lars, Halfvarson, Jonas, Askling, Johan, Ekbom, Anders, Sørensen, Henrik Toft, Ludvigsson, Jonas F., Olén, Ola, Erichsen, Rune, Sachs, Michael C., Pedersen, Lars, Halfvarson, Jonas, Askling, Johan, Ekbom, Anders, Sørensen, Henrik Toft, and Ludvigsson, Jonas F.
- Abstract
Background: Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance paradigms, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account, such as by assessing CRC incidence by tumour stage, or stage-adjusted mortality from CRC. We aimed to compare both overall and country-specific risks of CRC mortality and incident CRC among patients with UC. Methods: In this population-based cohort study of 96 447 patients with UC in Denmark (n=32 919) and Sweden (n=63 528), patients were followed up for CRC incidence and CRC mortality between Jan 1, 1969, and Dec 31, 2017, and compared with matched reference individuals from the general population (n=949 207). Patients with UC were selected from national registers and included in the analysis if they had two or more records with a relevant International Classification of Disease in the patient register (in the country in question) or one such record plus a colorectal biopsy report with a morphology code suggestive of inflammatory bowel disease. For every patient with UC, we selected matched reference individuals from the total population registers of Denmark and Sweden, who were matched for sex, age, birth year, and place of residence. We used Cox regression to compute hazard ratios (HRs) for incident CRC, and for CRC mortality, taking tumour stage into account. Findings: During follow-up, we observed 1336 incident CRCs in the UC cohort (1.29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0.82 per 1000 person-years; HR 1.66, 95% CI 1.57-1.76). In the UC cohort, 639 patients died from CRC (0.55 per 1000 person-years), compared with 4451 reference individuals (0.38 per 1000 person-years; HR 1.59, 95% CI 1.46-1.72) during the same time period. The CRC stage distribution in people with UC was less advanced (p<0.0001) than in matched reference individuals, but taking tumour stage, Funding Agencies:Swedish Medical Society (Fund for Research in Gastroenterology) Swedish Medical Society (Ihre Foundation) Mag-tarmfonden Young Scholar Award from the Strategic Research Area Epidemiology programme at Karolinska Institutet Independent Research Fund Denmark
- Published
- 2020
- Full Text
- View/download PDF
244. Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients
- Author
-
Halfvarson, Jonas, Lundström, Maria Ling, Lampinen, Maria, Schoultz, Ida, Bodin, Lennart, Carlson, Marie, Halfvarson, Jonas, Lundström, Maria Ling, Lampinen, Maria, Schoultz, Ida, Bodin, Lennart, and Carlson, Marie
- Abstract
Objective To examine the role of eosinophils in the pre-diagnostic phase of inflammatory bowel disease (IBD), we studied the influence of genetic and shared environmental risk factors in a twin cohort of IBD. Material and methods We analysed eosinophil derived neurotoxin (EDN) and eosinophil cationic protein (ECP) in faecal samples from twin pairs with Crohn's disease (n = 37) or ulcerative colitis (n = 21) and from external healthy controls (n = 44). Eosinophils stained with eosinophil peroxidase (EPO) were quantified in rectal biopsies. Ratios with 95% confidence intervals were calculated. Results Twins with Crohn' disease displayed higher levels of EDN (Ratio = 2.98, 1.65-5.37) and ECP (Ratio 1.83, 1.24-2.70) than their healthy siblings. Levels did not differ between healthy twin-siblings and external controls (EDN, Ratio = 1.52, 0.79-2.94 and ECP, Ratio = 0.93, 0.56-1.54). Higher levels of EDN (Ratio = 2.43, 1.13-5.24) and ECP (Ratio = 1.53, 0.92-2.53) were observed among twins with ulcerative colitis vs their healthy siblings. Levels did not differ between healthy twin-siblings and external controls (EDN, Ratio = 1.08, 0.51-2.25 and ECP, Ratio = 1.29, 0.74-2.26). Using intra-class correlation coefficient (ICC), we found no agreement in levels of EDN or ECP in discordant pairs, except for ECP in monozygotic Crohn's disease pairs (ICC = 0.63). In contrast, agreement was observed in monozygotic pairs concordant for Crohn's disease (EDN, ICC = 0.67 and ECP, ICC = 0.66). The number of eosinophils in rectum was increased in twins with ulcerative colitis vs their healthy sibling (Ratio = 2.22, 1.50-3.27). Conclusions Activation of eosinophils in IBD seems to be a consequence of inflammation rather than an effect of genetic and shared environmental risk factors alone.
- Published
- 2020
- Full Text
- View/download PDF
245. The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
- Author
-
Kim, HoUng, Alten, Rieke, Avedano, Luisa, Dignass, Axel Uwe, Gomollón, Fernando, Greveson, Kay, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Lakatos, Peter Laszlo, Lee, JongHyuk, Makri, Souzi, Parker, Ben, Peyrin‑Biroulet, Laurent, Schreiber, Stefan, Simoens, Steven, Westhovens, Rene, Danese, Silvio, Jeong, Ji Hoon, Kim, HoUng, Alten, Rieke, Avedano, Luisa, Dignass, Axel Uwe, Gomollón, Fernando, Greveson, Kay, Halfvarson, Jonas, Irving, Peter M., Jahnsen, Jørgen, Lakatos, Peter Laszlo, Lee, JongHyuk, Makri, Souzi, Parker, Ben, Peyrin‑Biroulet, Laurent, Schreiber, Stefan, Simoens, Steven, Westhovens, Rene, Danese, Silvio, and Jeong, Ji Hoon
- Abstract
Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators—can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.
- Published
- 2020
246. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up:a population-based study
- Author
-
Burisch, Johan, Vardi, Hillel, Schwartz, Doron, Friger, Michael, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-rousseau, Corinne, Lakatos, Laszlo, Lakatos, Peter L, D'incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Chetcuti Zammit, Stefania, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Midjord, Jóngerð Maria Miné, Nielsen, Kári Rubek, Winther Andersen, Karina, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Domislovic, Viktor, Krznaric, Zeljko, Sebastian, Shaji, Oksanen, Pia, Collin, Pekka, Barros, Luisa, Magro, Fernando, Salupere, Riina, Kievit, Hendrika Adriana Linda, Goldis, Adrian, Kaimakliotis, Ioannis P, Dahlerup, Jens F, Eriksson, Carl, Halfvarson, Jonas, Fernandez, Alberto, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, Langholz, Ebbe, Munkholm, Pia, Odes, Selwyn, Turk, Niksa, Vind, Ida, Burisch, Johan, Vardi, Hillel, Schwartz, Doron, Friger, Michael, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-rousseau, Corinne, Lakatos, Laszlo, Lakatos, Peter L, D'incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Chetcuti Zammit, Stefania, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Midjord, Jóngerð Maria Miné, Nielsen, Kári Rubek, Winther Andersen, Karina, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Domislovic, Viktor, Krznaric, Zeljko, Sebastian, Shaji, Oksanen, Pia, Collin, Pekka, Barros, Luisa, Magro, Fernando, Salupere, Riina, Kievit, Hendrika Adriana Linda, Goldis, Adrian, Kaimakliotis, Ioannis P, Dahlerup, Jens F, Eriksson, Carl, Halfvarson, Jonas, Fernandez, Alberto, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, Langholz, Ebbe, Munkholm, Pia, Odes, Selwyn, Turk, Niksa, and Vind, Ida
- Published
- 2020
247. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study
- Author
-
Burisch, Johan, Bergemalm, Daniel, Halfvarson, Jonas, Domislovic, Viktor, Krznaric, Zeljko, Goldis, Adrian, Dahlerup, Jens F, Oksanen, Pia, Collin, Pekka, de Castro, Luisa, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, D'Incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Misra, Ravi, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Gatt, Kelly, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Andersen, Karina W, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Sebastian, Shaji, Barros, Luisa, Magro, Fernando, Midjord, Jóngerð Mm, Nielsen, Kári R, Salupere, Riina, Kievit, Hendrika Al, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-Rousseau, Corinne, Kaimakliotis, Ioannis P, Schwartz, Doron, Odes, Selwyn, Lakatos, Laszlo, Lakatos, Peter L, Langholz, Ebbe, Munkholm, Pia, Burisch, Johan, Bergemalm, Daniel, Halfvarson, Jonas, Domislovic, Viktor, Krznaric, Zeljko, Goldis, Adrian, Dahlerup, Jens F, Oksanen, Pia, Collin, Pekka, de Castro, Luisa, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, D'Incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Misra, Ravi, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Gatt, Kelly, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Andersen, Karina W, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Sebastian, Shaji, Barros, Luisa, Magro, Fernando, Midjord, Jóngerð Mm, Nielsen, Kári R, Salupere, Riina, Kievit, Hendrika Al, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-Rousseau, Corinne, Kaimakliotis, Ioannis P, Schwartz, Doron, Odes, Selwyn, Lakatos, Laszlo, Lakatos, Peter L, Langholz, Ebbe, and Munkholm, Pia
- Abstract
BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, i
- Published
- 2020
248. Real-world effectiveness of vedolizumab in ulcerative colitis : Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study
- Author
-
Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Udumyan, Ruzan, Karlén, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Hjortswang, H., Halfvarson, Jonas, Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Udumyan, Ruzan, Karlén, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Hjortswang, H., and Halfvarson, Jonas
- Published
- 2020
- Full Text
- View/download PDF
249. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
- Author
-
Vatn, S., Carstens, Adam, Kristoffersen, A. B., Bergemalm, Daniel, Casén, C., Moen, A. E. F., Tannaes, T. M., Lindstrøm, J., Detlie, T. E., Olbjørn, C., Lindqvist, Carl Mårten, Söderholm, J. D., Gomollón, F., Kalla, R., Satsangi, J., Vatn, M. H., Jahnsen, J., Halfvarson, Jonas, Ricanek, P., Vatn, S., Carstens, Adam, Kristoffersen, A. B., Bergemalm, Daniel, Casén, C., Moen, A. E. F., Tannaes, T. M., Lindstrøm, J., Detlie, T. E., Olbjørn, C., Lindqvist, Carl Mårten, Söderholm, J. D., Gomollón, F., Kalla, R., Satsangi, J., Vatn, M. H., Jahnsen, J., Halfvarson, Jonas, and Ricanek, P.
- Abstract
Method: We examined faecal samples, using the GA-map (TM) Dysbiosis Test, to associate gut microbiota composition with Crohn's disease (CD) and ulcerative colitis (UC) and to identify markers for future biomarker identification. We conducted a prospective case-control study (EU-ref. no. 305676) in an inception cohort of 324 individuals (64 CD, 84 UC, 116 symptomatic non-IBD controls and 44 healthy controls) across five European centres and examined 54 predetermined bacterial markers. We categorized patients according to the Montreal Classification and calculated the dysbiosis index (DI). Non-parametric tests were used to compare groups and the Bonferroni correction to adjust for multiple comparisons. Results: The fluorescent signals (FSSs) for Firmicutes and Eubacterium hallii were lower in inflammatory bowel disease (IBD) vs. symptomatic controls (p<.05). FSS for Firmicutes, Lachnospiraceae, Eubacterium hallii and Ruminococcus albus/bromii were lower, whereas the signal fo rBacteroides Fragilis was higher in UC vs. symptomatic controls (p<.05). FSS was higher for Bifidobacterium spp., Eubacterium hallii, Actinobacteria and Firmicutes among patients with ulcerative proctitis, compared to extensive colitis (p<.05). In CD, we observed no association with disease location. The DI correlated with faecal-calprotectin in both CD and in UC (p<.001). In terms of treatment escalation and anti-TNF response, differences were observed for some bacterial markers, but none of these associations were statistically significant. Conclusion: Our data reveal that the GA-map (TM) Dysbiosis Test holds the potential to characterize the faecal microbiota composition and to assess the degree of dysbiosis in new-onset IBD. On the other hand, our results cannot demonstrate any proven diagnostic or predictive value of this method to support clinical decision making., Funding Agency:European Union (EU) 2858546
- Published
- 2020
- Full Text
- View/download PDF
250. Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in inflammatory bowel disease
- Author
-
Kalla, R., Adams, A. T., Ventham, N. T., Kennedy, N. A., White, R., Clarke, C., Ivens, A., Bergemalm, Daniel, Vatn, S., Lopez-Jimena, B., Ricanek, P., Vatn, M. H., Söderholm, J., Gomollón, F., Nowak, J. K., Jahnsen, J., Halfvarson, Jonas, McTaggart, S., Ho, G. T., Buck, A., Satsangi, J., Kalla, R., Adams, A. T., Ventham, N. T., Kennedy, N. A., White, R., Clarke, C., Ivens, A., Bergemalm, Daniel, Vatn, S., Lopez-Jimena, B., Ricanek, P., Vatn, M. H., Söderholm, J., Gomollón, F., Nowak, J. K., Jahnsen, J., Halfvarson, Jonas, McTaggart, S., Ho, G. T., Buck, A., and Satsangi, J.
- Abstract
BACKGROUND: MicroRNAs (miRNAs) are cell-specific small non-coding RNAs that can regulate gene expression and have been implicated in Inflammatory Bowel Disease (IBD) pathogenesis. In our study, we define the cell-specific miRNA profiles and investigate its biomarker potential in IBD. METHODS: In a 2-stage prospective multi-centre case control study, Next Generation sequencing was performed on a discovery cohort of immunomagnetically separated leucocytes from 32 patients (9 CD, 14 UC, 8 healthy controls) and differentially expressed signals were validated in whole blood in 294 patients (97 UC, 98 CD, 98 non-IBD) using quantitative PCR. Correlations were analysed with phenotype, including need for early treatment escalation as a marker of progressive disease using Cox proportional hazards. RESULTS: In stage 1, each leucocyte subset (CD4+ and CD8+ T-cells and CD14+ monocytes) was analysed in IBD and controls. Three specific miRNAs differentiated IBD from controls in CD4+ T-cells, including miR-1307-3p (p=0.01), miR-3615 (p=0.02) and miR-4792 (p=0.01). In the extension cohort, in stage 2, miR-1307-3p was able to predict disease progression in IBD (HR 1.98, IQR:1.20-3.27;logrank p=1.80×10-3), in particular CD (HR 2.81; IQR: 1.11-3.53, p=6.50×10-4). Using blood-based multimarker miRNA models, the estimated chance of escalation in CD was 83% if 2 or more criteria were met and 90% for UC if 3 or more criteria are met. INTERPRETATION: We have identified and validated unique CD4+ T-cell miRNAs that are differentially regulated in IBD. These miRNAs may be able to predict treatment escalation and have the potential for clinical translation; further prospective evaluation is now indicated., Funding Agencies:Crohn's and Colitis UK [CCUK] M2016/2Biotechnology and Biological Sciences Research Council (BBSRC)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.